Recent News

• 03.12.2026 - Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
• 03.12.2026 - Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
• 03.12.2026 - Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
• 03.12.2026 - Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
• 03.10.2026 - Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
• 03.10.2026 - Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
• 03.10.2026 - Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
• 03.09.2026 - Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
• 03.09.2026 - Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
• 02.24.2026 - Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference

Recent Filings

• 03.12.2026 - EX-99.1 EX-99.1
• 03.12.2026 - 8-K Current report
• 03.10.2026 - 8-K Current report
• 03.10.2026 - EX-99.1 EX-99.1
• 02.26.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.30.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 01.26.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors